title: A Multicenter, Randomized, Open-label Phase 2 Study Evaluating the Safety and Efficacy of Three Different Regimens of Oral Panobinostat in Combination With Subcutaneous Bortezomib and Oral Dexamethasone in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma Who Have Been Previously Exposed to Immunomodulatory Agents

summary:
The purpose of this study is to investigate the safety and efficacy of three different regimens of PAN (20 mg TIW, 20 mg BIW, and 10 mg TIW) in combination with s.c. BTZ and Dex and to provide exposure, safety and efficacy data to identify the optimal regimen of PAN in a randomized, 3-arm parallel design. This study will also assess the impact of administering s.c. BTZ (in combination with PAN and Dex) twice weekly for 4 cycles, and then weekly starting from Cycle 5 until disease progression in patients ≤ 75 years of age. Patients > 75 years of age will receive for the entire treatment period s.c. BTZ weekly (in combination with PAN and Dex) until disease progression.

Patients will be treated until disease progression or until they discontinue earlier due to unacceptable toxicity or for other reasons.

Patients who discontinued study treatment for reasons other than disease progression will be followed for efficacy every 6 weeks.

All patients will be followed for survival until the last patient entering long-term follow-up has completed a 3 year survival follow-up or discontinued earlier.

ReferenceCitation: Laubach JP, Schjesvold F, Mariz M, Dimopoulos MA, Lech-Maranda E, Spicka I, Hungria VTM, Shelekhova T, Abdo A, Jacobasch L, Polprasert C, Hájek R, Illés Á, Wróbel T, Sureda A, Beksac M, Gonçalves IZ, Bladé J, Rajkumar SV, Chari A, Lonial S, Spencer A, Maison-Blanche P, Moreau P, San-Miguel JF, Richardson PG. Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study. Lancet Oncol. 2021 Jan;22(1):142-154. doi: 10.1016/S1470-2045(20)30680-X. Epub 2020 Dec 7.

family: Laubach

full_name: Jacob P Laubach

given: Jacob P

family: Schjesvold

full_name: Fredrik Schjesvold

given: Fredrik

family: Mariz

full_name: Mário Mariz

given: Mário

family: Dimopoulos

full_name: Meletios A Dimopoulos

given: Meletios A

family: Lech-Maranda

full_name: Ewa Lech-Maranda

given: Ewa

family: Spicka

full_name: Ivan Spicka

given: Ivan

family: Hungria

full_name: Vania T M Hungria

given: Vania T M

family: Shelekhova

full_name: Tatiana Shelekhova

given: Tatiana

family: Abdo

full_name: Andre Abdo

given: Andre

family: Jacobasch

full_name: Lutz Jacobasch

given: Lutz

family: Polprasert

full_name: Chantana Polprasert

given: Chantana

family: Hájek

full_name: Roman Hájek

given: Roman

family: Illés

full_name: Árpád Illés

given: Árpád

family: Wróbel

full_name: Tomasz Wróbel

given: Tomasz

family: Sureda

full_name: Anna Sureda

given: Anna

family: Beksac

full_name: Meral Beksac

given: Meral

family: Gonçalves

full_name: Iara Z Gonçalves

given: Iara Z

family: Bladé

full_name: Joan Bladé

given: Joan

family: Rajkumar

full_name: S Vincent Rajkumar

given: S Vincent

family: Chari

full_name: Ajai Chari

given: Ajai

family: Lonial

full_name: Sagar Lonial

given: Sagar

family: Spencer

full_name: Andrew Spencer

given: Andrew

family: Maison-Blanche

full_name: Pierre Maison-Blanche

given: Pierre

ipd_sharing_description:
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

location_country:
Greece
Belgium
Australia
Russian Federation
France
Poland
Thailand
Norway
Canada
Korea, Republic of
Sweden
Netherlands
Hungary
Portugal
United States
Germany
Italy
Brazil
Lebanon
Czechia
Spain
Turkey

location_facility: Albert Schweitzer ziekenhuis, Hematology


title: Phase 1b/2 Trial of IPH2201 And Cetuximab in Patients With Human Papillomavirus (HPV) (+) and HPV (-) Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

summary:
The objective of this study is to evaluate in a 3 +3 design, the safety of escalating doses of Monalizumab given IV in combination with cetuximab in patients who have received prior systemic regimen(s) for recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN).

Cohorts expansion will evaluate antitumor activity of monalizumab and cetuximab with or without anti-PD(L)1

status: Active, not recruiting

study_completion_date_type: Anticipated

study_type: Interventional

design_allocation: Non-Randomized

primary_purpose: Treatment

enrollment_type: Actual

lead_sponsor: Innate Pharma

location_country:
United States
France

location_facility: Washington University School of Medicine

location_facility: University of California, Moores Cancer Center

location_facility: University of Maryland, Greenebaum Comprehensive Cancer Center

location_facility: Institut Regional du Cancer de Montpellier

intervention_type: Biological

lead_sponsor_type: industriel

status_simplified: Ongoing


design_allocation: Randomized

intervention_type: Drug

study_start_date_type: Actual

lead_sponsor: Karyopharm Therapeutics Inc

location_country:
Italy
United States
Sweden
Germany
France
Israel
Belgium
Spain
Canada
United Kingdom

acronym: SEAL

location_facility: National Center for Tumor Diseases, Univeristy Hospital Heidelberg

location_facility: Cambridge University Hospitals NHS Foundation Trust

location_facility: University of Pittsburgh Medical Center (UPMC)

location_facility: Cross Cancer Center - Alberta Health Services

location_facility: Policlinico Universitario Campus Biomedico

location_facility: Klinik und Poliklinik für Innere Medizin III, Hämatologie und Onkologie Klinikum rechts der Isar der TU Muenchen

location_facility: James Cancer Center, Ohio State University

location_facility: Technische Universitaet Dresden Med. Fakultaet Carl Gustav Carus Med. Klinik u. Poliklinik I

location_facility: U.O.C. Oncologia Medica Oncology Department

location_facility: Institut Régional du Cancer de Montpellier (ICM)

location_facility: Hospital Universitario Clínico San Carlos

location_facility: "Germans Trias Pujol" University Hospital

ipd_sharing: Undecided

type: EudraCT Number

source: euctr

title: A Phase 2-3, Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) Versus Placebo in Patients With Advanced Unresectable Dedifferentiated Liposarcoma (DDLS)

summary: This is a randomized, multicenter, double-blind, placebo-controlled, Phase 2-3 study of patients diagnosed with advanced unresectable dedifferentiated liposarcoma. Approximately 342 total patients will be randomized to study treatment (selinexor or placebo).


status: Terminated

lead_sponsor: Novartis Pharmaceuticals

location_country:
Greece
Australia
Belgium
Russian Federation
Denmark
Taiwan
France
Japan
Poland
Norway
Canada
Sweden
Hong Kong
Switzerland
Singapore
Hungary
Portugal
Germany
United Kingdom
Italy
Austria
Brazil
Israel
Spain
Turkey

acronym: ReTHINK

ipd_sharing: Yes

study_completion_date_type: Actual

title: A Randomized, Double Blind, Placebo-controlled, Multicenter, Phase III Study Investigating the Efficacy and Safety of Ruxolitinib in Early Myelofibrosis Patients With High Molecular Risk Mutations

summary: Myelofibrosis patients with high molecular risk mutations have an intrinsically aggressive disease with increased risk of leukemic transformation and reduced overall survival. As there are no therapies currently established in the subset of high molecular risk patients with early myelofibrosis, the study aimed to evaluate ruxolitinib in this patient population.

status_simplified: Unknown


lead_sponsor: Seagen Inc.

location_country:
Italy
France
Czechia
Poland
Spain
United States
United Kingdom

location_facility: Centre Hospitalier Regional Universitaire (CHRU) Brest - Hopital Morvan

location_facility: Centre Hospitalier Universitaire de Nantes (CHU Nantes) - Hotel Dieu

location_facility: Hospital Clinico Universitario Lozano Blesa de Zaragoza

location_facility: Oncology and Hematology Associates of Southwest Virginia, Inc.

location_facility: Azienda Ospedaliera Spedali Civili di Brescia

location_facility: A.O Ospadale Di Circolo E Fondazione Macchi

location_facility: University Hospital's Birmingham NHS Foundation trust-Queen Elizabeth Hospital

location_facility: Willamette Valley Cancer Institute and Research Center

location_facility: Azienda Ospedaliero-Universitaria di Bologna - Policlinico S.Orsola-Malpighi

location_facility: Centre Hospitalier Universitaire (CHU) de Poitier- Hopital de la Miletrie - Hopital Jean Bernard

location_facility: Hematology and Oncology Associates of Northern New Jersey, P.A.

location_facility: Centre Hospitalier Universitaire de Rennes, Hôpital Pontchaillou

location_facility: The Oncology Institute of Hope and Innovation

location_facility: IRCCS Ospedale Casa Sollievo della Sofferenza

location_facility: Greenville Health System Institutional Review Board

title: A Randomized, Open Label, Phase 2 Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for Relapsed or Refractory CD30-Positive Diffuse Large B-Cell Lymphoma

summary: This is a randomized, open-label, multicenter, Phase 2 clinical trial designed to evaluate the efficacy and safety of brentuximab vedotin in combination with rituximab and bendamustine for the treatment of patients with relapsed or refractory CD30-positive diffuse large B-cell lymphoma (DLBCL) after failure of second-line salvage therapy or as second-line treatment in patients ineligible for autologous stem cell transplant (ASCT).


ReferenceType: derived

ReferenceCitation: Schmidt AF, Carter JL, Pearce LS, Wilkins JT, Overington JP, Hingorani AD, Casas JP. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2020 Oct 20;10:CD011748. doi: 10.1002/14651858.CD011748.pub3.

name: Institute of Cardiovascular Science; University College London; London UK

name: Department of Cardiology, Division Heart and Lungs; UMC Utrecht; Utrecht Netherlands

family: Schmidt

full_name: Amand F Schmidt

given: Amand F

sequence: additional

name: Department of Clinical Pharmacology and Therapeutics; University College London Hospital; London UK

family: Carter

full_name: John-Paul L Carter

given: John-Paul L

name: Department of Non-communicable Disease Epidemiology; London School of Hygiene & Tropical Medicine; London UK

family: Pearce

full_name: Lucy S Pearce

given: Lucy S

name: The Department of Medicine (Cardiology) and the Department of Preventive Medicine; Northwestern University Feinberg School of Medicine; Chicago Illinois USA

family: Wilkins

full_name: John T Wilkins

given: John T

name: Medicines Discovery Catapult; Alderly Edge UK

family: Overington

full_name: John P Overington

given: John P

family: Hingorani

full_name: Aroon D Hingorani

given: Aroon D

name: Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC); VA Boston Healthcare System; Boston Massachusetts USA

family: Casas

full_name: JP Casas

given: JP

bso_classification: Medical research

datasource: user

genre: journal-article

genre_raw: journal-article

journal_name: Cochrane Database of Systematic Reviews

oa_host_type: repository

evidence: oa repository (via OAI-PMH title and first author match)

host_type: repository

license_normalized: no license

repository_institution: University College London - UCL Discovery

repository_normalized: UCL Discovery

version: publishedVersion

repository_institution: University of Groningen / Centre for Information Technology - University of Groningen research database

evidence: oa repository (via pmcid lookup)

repository_normalized: PubMed Central

version: acceptedVersion

publisher: Wiley

publisher_dissemination: Wiley

publisher_group: Wiley

publisher_normalized: Wiley

ReferenceCitation: Ray KK, Del Prato S, Müller-Wieland D, Cariou B, Colhoun HM, Tinahones FJ, Domenger C, Letierce A, Mandel J, Samuel R, Bujas-Bobanovic M, Leiter LA. Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies. Cardiovasc Diabetol. 2019 Nov 9;18(1):149. doi: 10.1186/s12933-019-0951-9.

family: Ray

full_name: Kausik K. Ray

given: Kausik K.

sequence: first

family: Del Prato

full_name: Stefano Del Prato

given: Stefano

family: Müller-Wieland

full_name: Dirk Müller-Wieland

given: Dirk

family: Cariou

full_name: Bertrand Cariou

given: Bertrand

family: Colhoun

full_name: Helen M. Colhoun

given: Helen M.

family: Tinahones

full_name: Francisco J. Tinahones

given: Francisco J.

family: Domenger

full_name: Catherine Domenger

given: Catherine

family: Letierce

full_name: Alexia Letierce

given: Alexia

family: Mandel

repository_institution: University of Edinburgh - Edinburgh Research Explorer

ReferenceCitation: Leiter LA, Cariou B, Müller-Wieland D, Colhoun HM, Del Prato S, Tinahones FJ, Ray KK, Bujas-Bobanovic M, Domenger C, Mandel J, Samuel R, Henry RR. Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM-INSULIN randomized trial. Diabetes Obes Metab. 2017 Dec;19(12):1781-1792. doi: 10.1111/dom.13114. Epub 2017 Oct 10.

name: Li Ka Shing Knowledge Institute, St. Michael's HospitalUniversity of Toronto Toronto Ontario Canada

name: Department of Endocrinology, l'institut du thoraxCHU Nantes, INSERM, CNRS, UNIV Nantes Nantes France

name: Department of Internal Medicine IUniversity Hospital RWTH Aachen Aachen Germany

name: Department of Clinical and Experimental MedicineUniversity of Pisa Pisa Italy

name: Hospital Virgen de la Victoria, CIBERobnMálaga University Málaga Spain

name: Department of Primary Care and Public HealthSchool of Public Health, Imperial College London London UK

name: IviData Stats Levallois‐Perret Paris France

name: Regeneron Pharmaceuticals, Inc. Tarrytown New York

name: University of California San Diego School of Medicine, and Center for Metabolic Research, Veterans Affairs, San Diego Healthcare System San Diego California

repository_institution: Le Centre pour la Communication Scientifique Directe - HAL - Archive ouverte HAL

title: Efficacy and safety of alirocumab in insulin‐treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM‐INSULIN randomized trial

location_country:
Italy
Austria
Switzerland
Netherlands
Germany
France
Belgium
Spain
United States
United Kingdom

location_facility:
Investigational Site Number 826007
Investigational Site Number 840016
Investigational Site Number 826015
Investigational Site Number 724001
Investigational Site Number 724011
Investigational Site Number 826012
Investigational Site Number 724010
Investigational Site Number 276006
Investigational Site Number 276015
Investigational Site Number 840011
Investigational Site Number 250-004
Investigational Site Number 840008
Investigational Site Number 380005
Investigational Site Number 040002
Investigational Site Number 056002
Investigational Site Number 276017
Investigational Site Number 380003
Investigational Site Number 040004
Investigational Site Number 840028
Investigational Site Number 276022
Investigational Site Number 056001
Investigational Site Number 724007
Investigational Site Number 840007
Investigational Site Number 276003
Investigational Site Number 724002
Investigational Site Number 276016
Investigational Site Number 276021
Investigational Site Number 276013
Investigational Site Number 250-001
Investigational Site Number 380008
Investigational Site Number 250-006
Investigational Site Number 840005
Investigational Site Number 840014
Investigational Site Number 528005
Investigational Site Number 840009
Investigational Site Number 724009
Investigational Site Number 826005
Investigational Site Number 840020
Investigational Site Number 840023
Investigational Site Number 276009
Investigational Site Number 276010
Investigational Site Number 826003
Investigational Site Number 040005
Investigational Site Number 250-007
Investigational Site Number 040003
Investigational Site Number 840001
Investigational Site Number 756003
Investigational Site Number 840018
Investigational Site Number 840010
Investigational Site Number 724003
Investigational Site Number 724005
Investigational Site Number 826002
Investigational Site Number 840013
Investigational Site Number 826004
Investigational Site Number 840019
Investigational Site Number 380012
Investigational Site Number 276002
Investigational Site Number 724012
Investigational Site Number 380011
Investigational Site Number 724008
Investigational Site Number 756001
Investigational Site Number 380001
Investigational Site Number 276018
Investigational Site Number 380004
Investigational Site Number 840021
Investigational Site Number 826010
Investigational Site Number 276019
Investigational Site Number 840015
Investigational Site Number 250-009
Investigational Site Number 276004
Investigational Site Number 528004
Investigational Site Number 380007
Investigational Site Number 380010
Investigational Site Number 724006
Investigational Site Number 840002
Investigational Site Number 826008
Investigational Site Number 276011
Investigational Site Number 276008
Investigational Site Number 724014
Investigational Site Number 380006
Investigational Site Number 380002
Investigational Site Number 840024
Investigational Site Number 840022
Investigational Site Number 826006
Investigational Site Number 250-008
Investigational Site Number 840027
Investigational Site Number 724013
Investigational Site Number 250-005
Investigational Site Number 826001
Investigational Site Number 840004
Investigational Site Number 840026
Investigational Site Number 250-002
Investigational Site Number 840003
Investigational Site Number 826009
Investigational Site Number 840017
Investigational Site Number 840029
Investigational Site Number 528003
Investigational Site Number 840006
Investigational Site Number 380009
Investigational Site Number 528002
Investigational Site Number 724004
Investigational Site Number 040001
Investigational Site Number 826011
Investigational Site Number 276005
Investigational Site Number 250-003
Investigational Site Number 840025
Investigational Site Number 056003
Investigational Site Number 840012
Investigational Site Number 528001
Investigational Site Number 276014

title: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab in Insulin Treated Patients With Type 1 or Type 2 Diabetes and With Hypercholesterolemia at High Cardiovascular Risk Not Adequately Controlled on Maximally Tolerated LDL-C Lowering Therapy

summary:
Primary Objectives:

To demonstrate the superiority of alirocumab in comparison with placebo in the reduction of calculated low-density lipoprotein cholesterol (LDL-C) in participants with diabetes treated with insulin and with hypercholesterolemia at high cardiovascular risk not adequately controlled on maximally tolerated LDL-C lowering therapy.
To evaluate the safety and tolerability of alirocumab in participants with diabetes treated with insulin.

Secondary Objective:

To demonstrate that alirocumab was superior in comparison to placebo in its effects on other lipid parameters (i.e., measured LDL-C, non-high-density lipoprotein cholesterol [non-HDL-C], apolipoprotein B [Apo B], total cholesterol [TC], lipoprotein a [Lp(a)], high density lipoprotein cholesterol [HDL-C], triglyceride [TG] levels, triglyceride rich lipoproteins [TGRL], apolipoprotein A-1 [Apo A-1], apolipoprotein C-III [Apo C-III], and LDL particle number and size).


title: A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Trial Investigating Two Doses of EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer (mCRPC)

acronym: PERSEUS

summary: The primary objective of the trial is to evaluate the clinical anti-tumor activity of EMD 525797 administered as 1-hour intravenous infusion every 3 weeks in terms of progression free survival (PFS) time in subjects with asymptomatic or mildly symptomatic metastatic castrate-resistant prostate cancer (mCRPC).

status: Completed

lead_sponsor: EMD Serono

location_country:
United States
South Africa
Netherlands
Germany
France
Poland
Slovakia
Belgium
Australia
Russian Federation
Spain
Canada

location_facility: Universitätsklinikum Tübinger, Klinik und Poliklinik für Urologie

location_facility: Universitätsmedizin Charité, Campus Benjamin Franklin, Urologische Klinik and Poliklinik

location_facility: Krasnoyarsk State Medical University Oncology and Radiotherapy Territorial Dispensary

location_facility: State Institution of Healthcare Ivanovo Regional Oncology Dispensary

location_facility: Universitätsklinikum Carl Gustav Carus an der Techischen Universität Dresden, Klinik und Poliklinik für Urologie

location_facility: Hôpitaux Civils de Colmar-CH Louis Pasteur

intervention_type: Other

status_simplified: Completed


title: A Randomized, Double-blind, Double-dummy, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab to Demonstrate Efficacy After Twelve Weeks of Treatment, Compared to Placebo and Etanercept, and to Assess the Safety, Tolerability and Long-term Efficacy up to One Year in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis

acronym: FIXTURE

summary: This study will assess the safety and efficacy of secukinumab compared to placebo and etanercept in patients that have moderate to severe, chronic, plaque-type psoriasis.

ReferenceCitation: Houghton K, Patil D, Gomez B, Feldman SR. Correlation Between Change in Psoriasis Area and Severity Index and Dermatology Life Quality Index in Patients with Psoriasis: Pooled Analysis from Four Phase 3 Clinical Trials of Secukinumab. Dermatol Ther (Heidelb). 2021 Aug;11(4):1373-1384. doi: 10.1007/s13555-021-00564-2. Epub 2021 Jun 10.

family: Houghton

full_name: Katherine Houghton

given: Katherine

family: Patil

full_name: Dhaval Patil

given: Dhaval

family: Gomez

full_name: Braulio Gomez

given: Braulio

family: Feldman

full_name: Steven R. Feldman

given: Steven R.

journal_name: Dermatology and Therapy

oa_colors: green gold

oa_host_type: publisher;repository

evidence: oa journal (via doaj)

host_type: publisher

license: cc-by-nc

license_normalized: cc-by-nc

publisher: Springer Science and Business Media LLC

publisher_dissemination: Springer-Nature

publisher_group: Springer-Nature

publisher_normalized: Springer

ReferenceCitation: Dehlin M, Fasth AER, Reinhardt M, Jacobsson LTH. Impact of psoriasis disease activity and other risk factors on serum urate levels in patients with psoriasis and psoriatic arthritis-a post-hoc analysis of pooled data from three phase 3 trials with secukinumab. Rheumatol Adv Pract. 2021 Feb 18;5(1):rkab009. doi: 10.1093/rap/rkab009. eCollection 2021.

apc_source: doaj

name: Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

family: Dehlin

full_name: Mats Dehlin

given: Mats

name: Medical Affairs, Novartis Sverige AB, Kista, Sweden

family: Fasth

full_name: Andreas E R Fasth

given: Andreas E R

family: Reinhardt

full_name: Maximilian Reinhardt

given: Maximilian

family: Jacobsson

full_name: Lennart T H Jacobsson

given: Lennart T H

currency_apc_doaj: GBP

journal_name: Rheumatology Advances in Practice

license: cc-by

license_normalized: cc-by

publisher: Oxford University Press (OUP)

publisher_dissemination: Oxford University Press

publisher_group: Oxford University Press

publisher_normalized: Oxford University Press

title: Impact of psoriasis disease activity and other risk factors on serum urate levels in patients with psoriasis and psoriatic arthritis—a post-hoc analysis of pooled data from three phase 3 trials with secukinumab

ReferenceCitation: Augustin M, Thaci D, Eyerich K, Pinter A, Radtke M, Lauffer F, Mrowietz U, Gerdes S, Pariser D, Lebwohl M, Sieder C, Melzer N, Reich K. Continued treatment with secukinumab is associated with high retention or regain of response. Br J Dermatol. 2020 Jan;182(1):67-75. doi: 10.1111/bjd.17991. Epub 2019 Jul 17.

name: Institute of Health Services Research in Dermatology and Nursing University Medical Center of Hamburg Eppendorf Germany

family: Augustin

full_name: M. Augustin

given: M.

name: Comprehensive Centre of Inflammation Medicine University of Lübeck Lübeck Germany

family: Thaci

full_name: D. Thaci

given: D.

name: Department of Dermatology and Allergy Technical University of Munich Munich Germany

family: Eyerich

full_name: K. Eyerich

given: K.

name: University Hospital Frankfurt Frankfurt am Main Germany

family: Pinter

full_name: A. Pinter

name: Psoriasis‐Center Department of Dermatology University Medical Center Schleswig‐Holstein Kiel Germany

name: Eastern Virginia Medical School and Virginia Clinical Research, Inc. Norfolk VA U.S.A.

name: Department of Dermatology Icahn School of Medicine at Mount Sinai New York U.S.A.

name: Dermatologikum Berlin and SCIderm Research Institute Hamburg Germany

ReferenceCitation: Menter A, Cather JC, Jarratt M, Meng X, Guana A, Nyirady J. Efficacy of Secukinumab on Moderate-to-severe Plaque Psoriasis Affecting Different Body Regions: a Pooled Analysis of Four Phase 3 Studies. Dermatol Ther (Heidelb). 2016 Dec;6(4):639-647. Epub 2016 Aug 30.

ReferenceCitation: Kircik L, Fowler J, Weiss J, Meng X, Guana A, Nyirady J. Efficacy of Secukinumab for Moderate-to-Severe Head and Neck Psoriasis Over 52 Weeks: Pooled Analysis of Four Phase 3 Studies. Dermatol Ther (Heidelb). 2016 Dec;6(4):627-638. Epub 2016 Aug 30.

ReferenceCitation: Gottlieb AB, Langley RG, Philipp S, Sigurgeirsson B, Blauvelt A, Martin R, Papavassilis C, Mpofu S. Secukinumab Improves Physical Function in Subjects With Plaque Psoriasis and Psoriatic Arthritis: Results from Two Randomized, Phase 3 Trials. J Drugs Dermatol. 2015 Aug;14(8):821-33.

ReferenceCitation: Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, Puig L, Nakagawa H, Spelman L, Sigurgeirsson B, Rivas E, Tsai TF, Wasel N, Tyring S, Salko T, Hampele I, Notter M, Karpov A, Helou S, Papavassilis C; ERASURE Study Group; FIXTURE Study Group. Secukinumab in plaque psoriasis--results of two phase 3 trials. N Engl J Med. 2014 Jul 24;371(4):326-38. doi: 10.1056/NEJMoa1314258. Epub 2014 Jul 9.

repository_institution: The University of Manchester - Research Explorer

title: Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials

location_country:
Guatemala
Finland
Romania
Belgium
Australia
Iceland
India
France
Poland
Argentina
Canada
Korea, Republic of
Colombia
Sweden
Philippines
Singapore
Hungary
United States
Germany
United Kingdom
Italy
Egypt
Spain


status: Recruiting

ipd_sharing_description: Eisai's data sharing commitment and further information on how to request data can be found on our website http://eisaiclinicaltrials.com/.

lead_sponsor: Eisai Inc.

enrollment_type: Anticipated

location_country:
Germany
France
Czechia
Belgium
Spain
Denmark
United States

location_facility: Wake Forest Baptist Medical Center - PPDS

location_facility: Centre Hospitalier Universitaire de Toulouse

location_facility: Children's Hospital of Richmond at VCU - CHoR-PIN

location_facility: Hospital General Universitario Gregorio Marañón

location_facility: University Hospitals Cleveland Medical Center

location_facility: Pediatric Epilepsy and Neurology Specialists

location_facility: Nemours Foundation Alfred Dupont Children's Hospital

location_facility: Hopitaux de Paris CHU Hopital Robert Debre - Inserm U676

location_facility: Meridian Clinical Research-(Savannah Georgia)

location_facility: Centro Medico Teknon - Grupo Quironsalud

location_facility: Hôpital Universitaire des Enfants Reine Fabiola

title: An Open-Label Study With Extension Phase to Evaluate the Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Subjects (Age 1 Month to Less Than 18 Years) With Childhood Epilepsy

summary: The purpose of the study is to evaluate the efficacy of perampanel as measured by the 50 percent (%) responder rate during the maintenance period of the core study for seizure frequency in participants with pediatric epileptic syndrome (Cohort 1) and partial-onset seizures (POS) (Cohort 2).


title: A Phase 3b, Multicenter, Open-Label, Single-Arm Study of Acalabrutinib (ACP-196) in Subjects With Chronic Lymphocytic Leukemia.

acronym: ASSURE

summary: This is a global, Phase 3b, multicenter, open-label, single-arm study to evaluate the safety and efficacy of acalabrutinib 100 mg bid in approximately 600 participants with chronic lymphocytic leukemia (CLL). Participants will be enrolled into 3 cohorts: treatment-naive (TN), relapsed/refractory (R/R), and prior Bruton tyrosine kinase inhibitor (BTKi) therapy. Participants will remain on study treatment until completion of 48 cycles (28 days per cycle), disease progression, toxicity requiring discontinuation, withdrawal of consent, lost to follow-up, death, or study termination by the sponsor whichever occurs first. The duration of the study will be approximately 72 months from the first participant enrolled. This duration includes an estimated 24-month recruitment time and an assumed 48 cycles of study treatment (28 days per cycle); additional study time will be accrued during the follow-up period for those participants remaining on study treatment after completion of 48 cycles (the amount of time will vary by participant)

ipd_sharing_description: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

lead_sponsor: AstraZeneca

location_country:
Italy
Brazil
United States
Sweden
Netherlands
Germany
Finland
France
Norway
Australia
Russian Federation
Spain
Denmark
Canada
United Kingdom
Korea, Republic of
Taiwan


title: A Randomized, Double-Blind, Factorial, Parallel-Group, Active and Placebo-Controlled, Multicenter Dose-Ranging Study to Evaluate the Efficacy, Safety and Tolerability of Six Dose Combinations of Solifenacin Succinate and Mirabegron Compared to Mirabegron and Solifenacin Succinate Monotherapies in the Treatment of Overactive Bladder.

acronym: Symphony

summary: The purpose of this study is to examine how well two medicines in combination (solifenacin succinate and mirabegron) work in the treatment of bladder problems over a 12-week period.

ReferenceCitation: Abrams P, Kelleher C, Staskin D, Rechberger T, Kay R, Martina R, Newgreen D, Paireddy A, van Maanen R, Ridder A. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony). Eur Urol. 2015 Mar;67(3):577-88. doi: 10.1016/j.eururo.2014.02.012. Epub 2014 Feb 19.

family: Abrams

full_name: Paul Abrams

given: Paul

family: Kelleher

full_name: Con Kelleher

given: Con

family: Staskin

full_name: David Staskin

given: David

family: Rechberger

full_name: Tomasz Rechberger

given: Tomasz

family: Kay

full_name: Richard Kay

given: Richard

family: Martina

full_name: Reynaldo Martina

given: Reynaldo

family: Newgreen

full_name: Donald Newgreen

given: Donald

family: Paireddy

full_name: Asha Paireddy

given: Asha

family: van Maanen

full_name: Rob van Maanen

given: Rob

family: Ridder

full_name: Arwin Ridder

given: Arwin

journal_name: European Urology

publisher: Elsevier BV

publisher_dissemination: Elsevier

publisher_group: Elsevier

publisher_normalized: Elsevier

title: Combination Treatment with Mirabegron and Solifenacin in Patients with Overactive Bladder: Efficacy and Safety Results from a Randomised, Double-blind, Dose-ranging, Phase 2 Study (Symphony)

ipd_sharing_description: Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as compounds terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Conditions and exceptions are described under the Sponsor Specific Details for Astellas on www.clinicalstudydatarequest.com.

lead_sponsor: Astellas Pharma Europe B.V.

location_country:
Italy
Sweden
Netherlands
Spain
Finland
France
Czechia
Poland
Slovakia
Norway
Hungary
Belgium
Romania
Russian Federation
Belarus
Denmark
Germany
United Kingdom
Portugal
Ukraine


title: A 52 Weeks, Double Blind, Randomized, Placebo-controlled Trial Evaluating the Effect of Oral BIBF 1120, 150 mg Twice Daily, on Annual Forced Vital Capacity Decline, in Patients With Idiopathic Pulmonary Fibrosis (IPF)

summary:
Idiopathic Pulmonary Fibrosis (IPF) is a chronic disease of unknown cause that results in scarring of the lung and there is a high unmet medical need for effective treatment to halt lung function decline, delay or avoid exacerbation (flare-ups), and ultimately to reduce the death rate.

In a large Phase 2 trial (1199.30) (NCT00514683), investigating the effects of 52 weeks of treatment with BIBF 1120 in patients with IPF, a positive effect was seen on lung function of patients treated with high dose of BIBF 1120 compared to placebo.

Hence it is the purpose of this trial to investigate and confirm the efficacy and safety of BIBF 1120 at a high dose in treating patients with IPF, compared with placebo. The trial will be conducted as a prospective, randomised design with the aim to collect safety and efficacy data.

Respiratory function is globally accepted for assessment of treatment effects in IPF patients. The chosen endpoint (Forced Vital Capacity (FVC) decline) is easy to obtain and is part of the usual examinations done in IPF patients.

ReferenceCitation: Glaspole I, Bonella F, Bargagli E, Glassberg MK, Caro F, Stansen W, Quaresma M, Orsatti L, Bendstrup E. Efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis who are elderly or have comorbidities. Respir Res. 2021 Apr 26;22(1):125. doi: 10.1186/s12931-021-01695-y.

family: Glaspole

full_name: Ian Glaspole

given: Ian

family: Bonella

full_name: Francesco Bonella

given: Francesco

family: Bargagli

full_name: Elena Bargagli

given: Elena

family: Glassberg

full_name: Marilyn K. Glassberg

given: Marilyn K.

family: Caro

full_name: Fabian Caro

given: Fabian

family: Stansen

full_name: Wibke Stansen

given: Wibke

family: Quaresma

full_name: Manuel Quaresma

given: Manuel

family: Orsatti

full_name: Leticia Orsatti

given: Leticia

family: Bendstrup

full_name: Elisabeth Bendstrup

given: Elisabeth

journal_name: Respiratory Research

ReferenceCitation: Jouneau S, Crestani B, Thibault R, Lederlin M, Vernhet L, Valenzuela C, Wijsenbeek M, Kreuter M, Stansen W, Quaresma M, Cottin V. Analysis of body mass index, weight loss and progression of idiopathic pulmonary fibrosis. Respir Res. 2020 Nov 25;21(1):312. doi: 10.1186/s12931-020-01528-4.

family: Jouneau

full_name: Stéphane Jouneau

given: Stéphane

family: Crestani

full_name: Bruno Crestani

given: Bruno

family: Thibault

full_name: Ronan Thibault

given: Ronan

family: Lederlin

full_name: Mathieu Lederlin

given: Mathieu

family: Vernhet

full_name: Laurent Vernhet

given: Laurent

family: Valenzuela

full_name: Claudia Valenzuela

given: Claudia

family: Wijsenbeek

full_name: Marlies Wijsenbeek

given: Marlies

family: Kreuter

full_name: Michael Kreuter

given: Michael

repository_institution: Le Centre pour la Communication Scientifique Directe - HAL - Inserm

ReferenceCitation: Brown KK, Martinez FJ, Walsh SLF, Thannickal VJ, Prasse A, Schlenker-Herceg R, Goeldner RG, Clerisme-Beaty E, Tetzlaff K, Cottin V, Wells AU. The natural history of progressive fibrosing interstitial lung diseases. Eur Respir J. 2020 Jun 25;55(6). pii: 2000085. doi: 10.1183/13993003.00085-2020. Print 2020 Jun.

repositories_institution:
Imperial College London - Spiral
PubMed Central - Europe PMC

ReferenceCitation: Richeldi L, Kolb M, Jouneau S, Wuyts WA, Schinzel B, Stowasser S, Quaresma M, Raghu G. Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis. BMC Pulm Med. 2020 Jan 8;20(1):3. doi: 10.1186/s12890-019-1030-4.

repository_institution: Università Cattolica del Sacro Cuore - PubliCatt

repository_institution: Le Centre pour la Communication Scientifique Directe - HAL - Université Paris Descartes

repository_institution: Le Centre pour la Communication Scientifique Directe - HAL - Inria

repositories:
HAL
LIRIAS (KU Leuven)
PubMed Central
publicatt.unicatt.it

repositories_institution: Università Cattolica del Sacro Cuore - PubliCatt

ReferenceCitation: Kreuter M, Koegler H, Trampisch M, Geier S, Richeldi L. Differing severities of acute exacerbations of idiopathic pulmonary fibrosis (IPF): insights from the INPULSIS® trials. Respir Res. 2019 Apr 11;20(1):71. doi: 10.1186/s12931-019-1037-7.

repository_institution: Heidelberg University - heiDOK - The Heidelberg Document Repository

ReferenceCitation: Xu Z, Li H, Wen F, Bai C, Chen P, Fan F, Hu N, Stowasser S, Kang J. Subgroup Analysis for Chinese Patients Included in the INPULSIS(®) Trials on Nintedanib in Idiopathic Pulmonary Fibrosis. Adv Ther. 2019 Mar;36(3):621-631. doi: 10.1007/s12325-019-0887-1. Epub 2019 Feb 7.

title: Subgroup Analysis for Chinese Patients Included in the INPULSIS® Trials on Nintedanib in Idiopathic Pulmonary Fibrosis

ReferenceCitation: Costabel U, Behr J, Crestani B, Stansen W, Schlenker-Herceg R, Stowasser S, Raghu G. Anti-acid therapy in idiopathic pulmonary fibrosis: insights from the INPULSIS® trials. Respir Res. 2018 Sep 3;19(1):167. doi: 10.1186/s12931-018-0866-0.

ReferenceCitation: Collard HR, Richeldi L, Kim DS, Taniguchi H, Tschoepe I, Luisetti M, Roman J, Tino G, Schlenker-Herceg R, Hallmann C, du Bois RM. Acute exacerbations in the INPULSIS trials of nintedanib in idiopathic pulmonary fibrosis. Eur Respir J. 2017 May 19;49(5). pii: 1601339. doi: 10.1183/13993003.01339-2016. Print 2017 May.

ReferenceCitation: Paterniti MO, Bi Y, Rekić D, Wang Y, Karimi-Shah BA, Chowdhury BA. Acute Exacerbation and Decline in Forced Vital Capacity Are Associated with Increased Mortality in Idiopathic Pulmonary Fibrosis. Ann Am Thorac Soc. 2017 Sep;14(9):1395-1402. doi: 10.1513/AnnalsATS.201606-458OC.

name: Division of Pulmonary, Allergy, and Rheumatology Products, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland; and

name: Division of Pharmacometrics, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland

ReferenceCitation: Rinciog C, Watkins M, Chang S, Maher TM, LeReun C, Esser D, Diamantopoulos A. A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK. Pharmacoeconomics. 2017 Apr;35(4):479-491. doi: 10.1007/s40273-016-0480-2.

repositories:
PubMed Central
UCL Discovery
spiral.imperial.ac.uk

repositories_institution: University College London - UCL Discovery

ReferenceCitation: Kolb M, Richeldi L, Behr J, Maher TM, Tang W, Stowasser S, Hallmann C, du Bois RM. Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume. Thorax. 2017 Apr;72(4):340-346. doi: 10.1136/thoraxjnl-2016-208710. Epub 2016 Sep 26.

repository_institution: University of Oxford - Oxford Academic Notes & Queries

repository_institution: University of Southampton - ePrints Soton

repositories_institution: University of Oxford - Oxford Academic Notes & Queries

repositories_institution: University of Southampton - ePrints Soton

ReferenceCitation: Corte T, Bonella F, Crestani B, Demedts MG, Richeldi L, Coeck C, Pelling K, Quaresma M, Lasky JA. Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis. Respir Res. 2015 Sep 24;16:116. doi: 10.1186/s12931-015-0276-5.

ReferenceCitation: Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y, Kim DS, Kolb M, Nicholson AG, Noble PW, Selman M, Taniguchi H, Brun M, Le Maulf F, Girard M, Stowasser S, Schlenker-Herceg R, Disse B, Collard HR; INPULSIS Trial Investigators. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014 May 29;370(22):2071-82. doi: 10.1056/NEJMoa1402584. Epub 2014 May 18. Erratum in: N Engl J Med. 2015 Aug 20;373(8):782.

repository_institution: University of Modena and Reggio Emilia - IRIS UNIMORE

repositories_institution: University of Modena and Reggio Emilia - IRIS UNIMORE

title: Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis

ReferenceCitation: Richeldi L, Cottin V, Flaherty KR, Kolb M, Inoue Y, Raghu G, Taniguchi H, Hansell DM, Nicholson AG, Le Maulf F, Stowasser S, Collard HR. Design of the INPULSIS™ trials: two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis. Respir Med. 2014 Jul;108(7):1023-30. doi: 10.1016/j.rmed.2014.04.011. Epub 2014 Apr 29.

title: Design of the INPULSIS™ trials: Two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis

location_country:
Italy
India
United Kingdom
Germany
France
Japan
Israel
Ireland
Belgium
Australia
China
United States
Czech Republic

location_facility: 1199.32.10038 Boehringer Ingelheim Investigational Site

location_facility: 1199.32.10034 Boehringer Ingelheim Investigational Site

location_facility: 1199.32.49001 Boehringer Ingelheim Investigational Site

location_facility: 1199.32.39006B Boehringer Ingelheim Investigational Site

location_facility: 1199.32.86006 Boehringer Ingelheim Investigational Site

location_facility: 1199.32.86004 Boehringer Ingelheim Investigational Site

location_facility: 1199.32.33002 Boehringer Ingelheim Investigational Site

location_facility: 1199.32.49005 Boehringer Ingelheim Investigational Site

location_facility: 1199.32.32001 Boehringer Ingelheim Investigational Site

location_facility: 1199.32.10025 Boehringer Ingelheim Investigational Site

location_facility: 1199.32.39001 Boehringer Ingelheim Investigational Site

location_facility: 1199.32.61001 Boehringer Ingelheim Investigational Site

location_facility: 1199.32.49002 Boehringer Ingelheim Investigational Site

location_facility: 1199.32.61002 Boehringer Ingelheim Investigational Site

location_facility: 1199.32.81006 Boehringer Ingelheim Investigational Site

location_facility: 1199.32.44002 Boehringer Ingelheim Investigational Site

location_facility: 1199.32.10003 Boehringer Ingelheim Investigational Site

location_facility: 1199.32.49004 Boehringer Ingelheim Investigational Site

location_facility: 1199.32.97001 Boehringer Ingelheim Investigational Site

location_facility: 1199.32.49008 Boehringer Ingelheim Investigational Site

location_facility: 1199.32.44003 Boehringer Ingelheim Investigational Site

location_facility: 1199.32.97004 Boehringer Ingelheim Investigational Site

location_facility: 1199.32.49007 Boehringer Ingelheim Investigational Site

location_facility: 1199.32.32005 Boehringer Ingelheim Investigational Site

location_facility: 1199.32.86005 Boehringer Ingelheim Investigational Site

location_facility: 1199.32.10021 Boehringer Ingelheim Investigational Site

location_facility: 1199.32.33006 Boehringer Ingelheim Investigational Site

location_facility: 1199.32.42003 Boehringer Ingelheim Investigational Site

location_facility: 1199.32.33001 Boehringer Ingelheim Investigational Site

location_facility: 1199.32.10001 Boehringer Ingelheim Investigational Site

location_facility: 1199.32.33005 Boehringer Ingelheim Investigational Site

location_facility: 1199.32.42002 Boehringer Ingelheim Investigational Site

location_facility: 1199.32.10024 Boehringer Ingelheim Investigational Site

location_facility: 1199.32.86001 Boehringer Ingelheim Investigational Site

location_facility: 1199.32.44005 Boehringer Ingelheim Investigational Site

location_facility: 1199.32.10008 Boehringer Ingelheim Investigational Site

location_facility: 1199.32.97002 Boehringer Ingelheim Investigational Site

location_facility: 1199.32.10022 Boehringer Ingelheim Investigational Site

location_facility: 1199.32.10005 Boehringer Ingelheim Investigational Site

location_facility: 1199.32.33004 Boehringer Ingelheim Investigational Site

location_facility: 1199.32.91005 Boehringer Ingelheim Investigational Site

location_facility: 1199.32.61005 Boehringer Ingelheim Investigational Site

location_facility: 1199.32.10033 Boehringer Ingelheim Investigational Site

location_facility: 1199.32.32002 Boehringer Ingelheim Investigational Site

location_facility: 1199.32.61003 Boehringer Ingelheim Investigational Site

location_facility: 1199.32.35301 Boehringer Ingelheim Investigational Site

location_facility: 1199.32.44004 Boehringer Ingelheim Investigational Site

location_facility: 1199.32.44009 Boehringer Ingelheim Investigational Site

location_facility: 1199.32.91001 Boehringer Ingelheim Investigational Site

location_facility: 1199.32.44006 Boehringer Ingelheim Investigational Site

location_facility: 1199.32.44008 Boehringer Ingelheim Investigational Site

location_facility: 1199.32.86002 Boehringer Ingelheim Investigational Site

location_facility: 1199.32.10016 Boehringer Ingelheim Investigational Site

location_facility: 1199.32.86003 Boehringer Ingelheim Investigational Site

location_facility: 1199.32.39007 Boehringer Ingelheim Investigational Site

location_facility: 1199.32.33007 Boehringer Ingelheim Investigational Site

location_facility: 1199.32.81007 Boehringer Ingelheim Investigational Site

location_facility: 1199.32.61004 Boehringer Ingelheim Investigational Site

location_facility: 1199.32.81001 Boehringer Ingelheim Investigational Site

location_facility: 1199.32.81002 Boehringer Ingelheim Investigational Site

location_facility: 1199.32.10015 Boehringer Ingelheim Investigational Site

location_facility: 1199.32.81010 Boehringer Ingelheim Investigational Site

location_facility: 1199.32.44001 Boehringer Ingelheim Investigational Site

location_facility: 1199.32.91003 Boehringer Ingelheim Investigational Site

location_facility: 1199.32.81008 Boehringer Ingelheim Investigational Site

location_facility: 1199.32.39006A Boehringer Ingelheim Investigational Site

location_facility: 1199.32.32004 Boehringer Ingelheim Investigational Site

location_facility: 1199.32.81005 Boehringer Ingelheim Investigational Site

location_facility: 1199.32.81004 Boehringer Ingelheim Investigational Site

location_facility: 1199.32.10029 Boehringer Ingelheim Investigational Site

location_facility: 1199.32.10002 Boehringer Ingelheim Investigational Site

location_facility: 1199.32.81012 Boehringer Ingelheim Investigational Site

location_facility: 1199.32.39011 Boehringer Ingelheim Investigational Site

location_facility: 1199.32.33003 Boehringer Ingelheim Investigational Site

location_facility: 1199.32.10023 Boehringer Ingelheim Investigational Site

location_facility: 1199.32.39010 Boehringer Ingelheim Investigational Site

location_facility: 1199.32.10020 Boehringer Ingelheim Investigational Site

location_facility: 1199.32.49006 Boehringer Ingelheim Investigational Site

location_facility: 1199.32.10019 Boehringer Ingelheim Investigational Site

location_facility: 1199.32.10004 Boehringer Ingelheim Investigational Site

location_facility: 1199.32.91006 Boehringer Ingelheim Investigational Site

location_facility: 1199.32.39008 Boehringer Ingelheim Investigational Site

location_facility: 1199.32.39005 Boehringer Ingelheim Investigational Site

location_facility: 1199.32.81011 Boehringer Ingelheim Investigational Site

location_facility: 1199.32.42001 Boehringer Ingelheim Investigational Site

location_facility: 1199.32.10018 Boehringer Ingelheim Investigational Site

location_facility: 1199.32.39002 Boehringer Ingelheim Investigational Site

location_facility: 1199.32.39004 Boehringer Ingelheim Investigational Site

location_facility: 1199.32.39012 Boehringer Ingelheim Investigational Site

location_facility: 1199.32.10007 Boehringer Ingelheim Investigational Site

location_facility: 1199.32.91002 Boehringer Ingelheim Investigational Site

location_facility: 1199.32.10028 Boehringer Ingelheim Investigational Site

location_facility: 1199.32.39009 Boehringer Ingelheim Investigational Site

location_facility: 1199.32.81009 Boehringer Ingelheim Investigational Site

location_facility: 1199.32.81003 Boehringer Ingelheim Investigational Site

location_facility: 1199.32.49003 Boehringer Ingelheim Investigational Site

location_facility: 1199.32.10013 Boehringer Ingelheim Investigational Site

location_facility: 1199.32.10009 Boehringer Ingelheim Investigational Site


ReferenceCitation: Strefford JC, Nowicka M, Hargreaves CE, Burton C, Davies A, Ganderton R, Hiddemann W, Iriyama C, Klapper W, Latham KV, Martelli M, Mir F, Parker H, Potter KN, Rose-Zerilli MJJ, Sehn LH, Trněný M, Vitolo U, Bolen CR, Klein C, Knapp A, Oestergaard MZ, Cragg MS. Single-nucleotide Fcγ receptor polymorphisms do not impact obinutuzumab/rituximab outcome in patients with lymphoma. Blood Adv. 2021 Aug 10;5(15):2935-2944. doi: 10.1182/bloodadvances.2020003985.

name: School of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom;

family: Strefford

full_name: Jonathan C. Strefford

given: Jonathan C.

name: F. Hoffmann-La Roche Ltd, Basel, Switzerland;

family: Nowicka

full_name: Malgorzata Nowicka

given: Malgorzata

name: Nuffield Department of Medicine, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom;

family: Hargreaves

full_name: Chantal E. Hargreaves

given: Chantal E.

name: Haematological Malignancy Diagnostic Service, Leeds Cancer Centre, Leeds, United Kingdom;

family: Burton

full_name: Cathy Burton

given: Cathy

name: Southampton Cancer Research United Kingdom (CRUK)/National Institute of Health Research (NIHR) Experimental Cancer Medicines Centre, University of Southampton, Southampton, United Kingdom;

family: Davies

full_name: Andrew Davies

given: Andrew

name: Southampton University Hospitals National Health Service (NHS) Foundation Trust, Southampton, United Kingdom;

family: Ganderton

full_name: Rosalind Ganderton

given: Rosalind

name: Department of Medicine III, Ludwig-Maximilians University Hospital Munich, Munich, Germany;

family: Hiddemann

full_name: Wolfgang Hiddemann

given: Wolfgang

name: Department of Pathology and Tumor Biology, Nagoya Graduate School of Medicine, Nagoya University, Nagoya, Japan;

family: Iriyama

full_name: Chisako Iriyama

given: Chisako

name: Department of Hematopathology, University of Kiel, Kiel, Germany;

family: Klapper

full_name: Wolfram Klapper

given: Wolfram

family: Latham

full_name: Kate V. Latham

given: Kate V.

name: Department of Translational and Precision Medicine, Section of Hematology, Sapienza University, Rome, Italy;

family: Martelli

full_name: Maurizio Martelli

given: Maurizio

name: Royal Marsden Hospital, London, United Kingdom;

family: Mir

full_name: Farheen Mir

given: Farheen

family: Parker

full_name: Helen Parker

given: Helen

family: Potter

full_name: Kathleen N. Potter

given: Kathleen N.

family: Rose-Zerilli

full_name: Matthew J. J. Rose-Zerilli

given: Matthew J. J.

name: Department of Medicine, University of British Columbia, Vancouver, BC, Canada;

family: Sehn

full_name: Laurie H. Sehn

given: Laurie H.

name: 1st Department of Medicine, 1st Faculty of Medicine, Charles University General Hospital, Prague, Czech Republic;

family: Trněný

full_name: Marek Trněný

given: Marek

name: Multidisciplinary Oncology Outpatient Clinic, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy;

family: Vitolo

full_name: Umberto Vitolo

given: Umberto

name: Genentech, Inc., South San Francisco, CA;

family: Bolen

full_name: Christopher R. Bolen

given: Christopher R.

name: Roche Innovation Center Zurich, Roche Glycart AG, Schlieren, Switzerland; and

family: Klein

full_name: Christian Klein

given: Christian

family: Knapp

full_name: Andrea Knapp

given: Andrea

family: Oestergaard

full_name: Mikkel Z. Oestergaard

given: Mikkel Z.

name: Antibody and Vaccine Group, Centre for Cancer Immunology, School of Cancer Sciences, University of Southampton Faculty of Medicine, University of Southampton, Southampton, United Kingdom

family: Cragg

full_name: Mark S. Cragg

given: Mark S.

journal_name: Blood Advances

ReferenceCitation: Davies A, Trask P, Demeter J, Florschütz A, Hänel M, Kinoshita T, Pettengell R, Quach H, Robinson S, Sadullah S, Sancho JM, Udvardy M, Witzens-Harig M, Knapp A, Liu W. Health-related quality of life in the phase III GALLIUM study of obinutuzumab- or rituximab-based chemotherapy in patients with previously untreated advanced follicular lymphoma. Ann Hematol. 2020 Dec;99(12):2837-2846. doi: 10.1007/s00277-020-04021-6. Epub 2020 Apr 20.

repository_institution: University of Melbourne - Minerva Access

repository_normalized: University of Melbourne - Minerva Access

repository_institution: St George's University of London - St George's Online Research Archive

repositories: University of Melbourne - Minerva Access

repositories_institution: St George's University of London - St George's Online Research Archive

repositories_institution: University of Melbourne - Minerva Access

ReferenceCitation: Klanova M, Oestergaard MZ, Trněný M, Hiddemann W, Marcus R, Sehn LH, Vitolo U, Bazeos A, Goede V, Zeuner H, Knapp A, Sahin D, Spielewoy N, Bolen CR, Cardona A, Klein C, Venstrom JM, Nielsen T, Fingerle-Rowson G. Prognostic Impact of Natural Killer Cell Count in Follicular Lymphoma and Diffuse Large B-cell Lymphoma Patients Treated with Immunochemotherapy. Clin Cancer Res. 2019 Aug 1;25(15):4634-4643. doi: 10.1158/1078-0432.CCR-18-3270. Epub 2019 May 3.

publisher: American Association for Cancer Research (AACR)

publisher_dissemination: American Association for Cancer Research

publisher_group: American Association for Cancer Research

publisher_normalized: American Association for Cancer Research

ReferenceCitation: Kusumoto S, Arcaini L, Hong X, Jin J, Kim WS, Kwong YL, Peters MG, Tanaka Y, Zelenetz AD, Kuriki H, Fingerle-Rowson G, Nielsen T, Ueda E, Piper-Lepoutre H, Sellam G, Tobinai K. Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy. Blood. 2019 Jan 10;133(2):137-146. doi: 10.1182/blood-2018-04-848044. Epub 2018 Oct 19.

name: Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan;

name: Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy;

name: Department of Molecular Medicine, University of Pavia, Pavia, Italy;

name: Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China;

name: Department of Hematology, The First Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, China;

name: Department of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea;

name: Department of Medicine, Queen Mary Hospital, Hong Kong, China;

name: Department of Medicine, University of California, San Francisco, San Francisco, CA;

name: Department of Virology and Liver Unit, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan;

name: Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY;

name: Department of Medicine, Weill Cornell Medical Center, New York, NY;

name: Clinical Science & Strategy Department, Oncology Clinical Science & Strategy, Chugai Pharmaceutical Co. Ltd., Tokyo, Japan;

name: Product Development Oncology, F. Hoffmann-La Roche Ltd., Basel, Switzerland; and

name: Department of Hematology, National Cancer Center Hospital, Tokyo, Japan

ReferenceCitation: Trotman J, Barrington SF, Belada D, Meignan M, MacEwan R, Owen C, Ptáčník V, Rosta A, Fingerle-Rowson GR, Zhu J, Nielsen T, Sahin D, Hiddemann W, Marcus RE, Davies A; PET investigators from the GALLIUM study. Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial. Lancet Oncol. 2018 Nov;19(11):1530-1542. doi: 10.1016/S1470-2045(18)30618-1. Epub 2018 Oct 8. Erratum in: Lancet Oncol. 2019 Apr 29;:.

repository_institution: Le Centre pour la Communication Scientifique Directe - HAL - CHU de Clermont-Ferrand

repositories_institution: Le Centre pour la Communication Scientifique Directe - HAL - Université Paris Descartes

ReferenceCitation: Hiddemann W, Barbui AM, Canales MA, Cannell PK, Collins GP, Dürig J, Forstpointner R, Herold M, Hertzberg M, Klanova M, Radford J, Seymour JF, Tobinai K, Trotman J, Burciu A, Fingerle-Rowson G, Wolbers M, Nielsen T, Marcus RE. Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety. J Clin Oncol. 2018 Aug 10;36(23):2395-2404. doi: 10.1200/JCO.2017.76.8960. Epub 2018 Jun 1.

name: Wolfgang Hiddemann and Roswitha Forstpointner, University Hospital, Ludwig Maximilian University Munich, Munich; Jan Dürig, University Hospital Essen, Essen; Michael Herold, HELIOS-Klinikum Erfurt, Erfurt, Germany; Anna Maria Barbui, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy; Miguel A. Canales, Hospital Universitario la Paz, Madrid, Spain; Paul K. Cannell, Fiona Stanley Hospital, Murdoch, Western Australia; Mark Hertzberg, Prince of Wales Hospital; Judith Trotman, Concord Repatriation...

repository_institution: Ludwid Maxmilian's Universitat Munchen - Open access LMU

repositories_institution: Ludwid Maxmilian's Universitat Munchen - Open access LMU

publisher: American Society of Clinical Oncology (ASCO)

publisher_dissemination: American Society of Clinical Oncology (ASCO)

publisher_group: American Society of Clinical Oncology (ASCO)

publisher_normalized: American Society of Clinical Oncology (ASCO)

ReferenceCitation: Marcus R, Davies A, Ando K, Klapper W, Opat S, Owen C, Phillips E, Sangha R, Schlag R, Seymour JF, Townsend W, Trněný M, Wenger M, Fingerle-Rowson G, Rufibach K, Moore T, Herold M, Hiddemann W. Obinutuzumab for the First-Line Treatment of Follicular Lymphoma. N Engl J Med. 2017 Oct 5;377(14):1331-1344. doi: 10.1056/NEJMoa1614598.

title: Obinutuzumab for the First-Line Treatment of Follicular Lymphoma

location_country:
Italy
United States
Sweden
Spain
Germany
Finland
France
Czechia
Japan
Israel
Hungary
Belgium
Australia
Russian Federation
China
Canada
United Kingdom
Taiwan

location_facility: Hopital Charles Lemoyne; Centre Integre de Lutte Contre Le Cancer de La Monteregie

location_facility: BAG Freiberg-Richter, Jacobasch, Illmer, Wolf; Gemeinschaftspraxis Hämatologie-Onkologie

location_facility: Klinikum Chemnitz gGmbH Krankenhaus Küchwald Klinik f.Innere Medizin III

location_facility: Institut für Versorgungsforschung in der Onkologie GbR Koblenz

location_facility: Royal Marsden Hospital; Dept of Medical Oncology

location_facility: Otto von Guericke Uni Magdeburg Uniklinik; Hämatologie/Onkologie

location_facility: The Cancer Institute Hospital of JFCR; Hematology Oncology

location_facility: National Institute of Oncology, A Dept of Internal Medicine

location_facility: Koo Foundation Sun Yat-Sen Cancer Center; Hemato-Oncology

location_facility: Churchill Hospital; Oxford Cancer and Haematology Centre

location_facility: Klinikum der Stadt Ludwigshafen; Medizinische Klinik A

location_facility: Aberdeen Royal Infirmary; Haematology - Ward 16

location_facility: Shanghai Jiao Tong University School of Medicine (SJTUSM) - Ruijin Hospital (GuangCi Hospital)

location_facility: Uni. der Johannes Gutenberg-Universitaet Mainz; III. Medizinische Klinik und Poliklinik

location_facility: General Hospital of Chinese PLA; Department of Hematology

location_facility: St James Uni Hospital; Icrf Cancer Medicine Research Unit

location_facility: University of Kansas; Medical Center & Medical pavilion

location_facility: Royal Cornwall Hospital; Haematology Clinic

location_facility: National Hospital Organization Kyushu Cancer Center; Hematology

location_facility: Western General Hospital; Department of Haematology

location_facility: Hiroshima University Hospital; Hematology

location_facility: James Paget Hospital; Haematology Department

location_facility: Universitätsklinikum Jena; Klinik für Innere Medizin II

location_facility: Aichi Cancer Center Hospital; Hematology and Cell Therapy

location_facility: University Hospital, Kyoto Prefectural University of Medicine; Hematology

location_facility: Southampton General Hospital; Medical Oncology

location_facility: Kliniken Ostalb, Stauferklinikum Schwäbisch-Gmünd; Zentrum für Innere Medizin

location_facility: Klinikum rechts der Isar der TU München; III. Medizinischen Klinik (Hämatologie/Onkologie)

location_facility: Klinikum St.Georg gGmbH Klinik für Internistische Onkologie und Hämotologie

location_facility: Helios Dr. Horst Schmidt Kliniken; Klinik Innere MED III: Hämatologie, Onkologie, Palliativmedizin

location_facility: Regional Clinical Hospital N.A. Semashko; Hematology

location_facility: The Regents of the University of California; Office of Research

location_facility: Sahlgrenska Universitetssjukhuset; Sektionen för hematologi och koagulation

location_facility: Toronto East General Hospital; Haematology/Oncology

location_facility: Gemeinschaftspraxis Dr. med. J. Mohm und Dr. med. G. Prange-Krex; Fachaerzte fuer Innere Medizin

location_facility: University College Hospital; Macmillan Cancer Centre

location_facility: Onkologischer Schwerpunkt am Oskar-Helene-Heim; Dres. Herrenberger, Keitel-Wittig u. Kirsch

location_facility: Universität Tübingen; Med. Klinik; Innere Medizin I

location_facility: National Cancer Center Hospital East;Hematology

location_facility: Universitätsklinikum Greifswald Klinik für Innere Medizin C und Poliklinik

location_facility: National Cancer Center Hospital; Hematology

location_facility: Hopital De La Conception; Hematologie Clinique

location_facility: Norfolk & Norwich Hospital; Dept of Haematology

location_facility: Hämatologisch-Onkologische Schwerpunktpraxis; Dres. Schlag & Schöttker

location_facility: Princess Alexandra Hospital; Department of Haematology

location_facility: Rambam Medical Center; Heamatology & Bone Marrow Transplantation

location_facility: Chang Gung Medical Foundation - Linkou; Division of Hematology- Oncology

location_facility: Kent & Canterbury Hospital; Clinical Haematology

location_facility: Shikoku Cancer Center; Hematology and Oncology

location_facility: A.O. Univ.Ospedali Riuniti Umerto I -G.M.Lancisi G.Salesi; U.O. Clinica Di Ematologia

location_facility: Peter MacCallum Cancer Centre; Department of Haematology

location_facility: Aomori Prefectural Central Hospital; Hematology

location_facility: Mannheimer Onkologie Praxis Dres. Jürgen Brust Dieter Schuster

location_facility: Az. Osp. S. Camillo Forlanini; Uo Ematologia E Trapianti Di Midollo Osseo

location_facility: Velindre NHS Trust; Haematology Department

location_facility: HELIOS Klinikum Erfurt I.Medizinische Klinik

location_facility: Hospital de Basurto; Servicio de Hematologia

location_facility: University of Debrecen Medical and Health Science Center, Institute of Internal Medicine, Hematology

location_facility: Queen Alexandra Hospital; Haematology and Oncology Centre

location_facility: Nagoya Daini Red Cross Hospital; Hematology & Oncology

location_facility: Christie Hospital; Breast Cancer Research Office

location_facility: Krankenhaus der Barmherzigen Brüder Trier; Innere Medizin I, Hämatologie / Internistische Onkologie

location_facility: Uniklinik Heidelberg, Medizinische Klinik & Poliklinik V

location_facility: Universitaetsklinikum des Saarlandes; medizinische Klinik und Poliklinik; Innere Medizin I

location_facility: Uni Degli Studi; Dip.Med.Clinica E Sperim. Ematologia

location_facility: Klinik der Uni zu Köln; Klinik für Innere Medizin

location_facility: Klinikum der Universität München, Campus Großhadern; Medizinische Klinik und Poliklinik III

location_facility: FSBI Russian Oncology Research Center n.a. Blokhin of MOH RF

location_facility: Pius-Hospital; Klinik fuer Haematologie und Onkologie

location_facility: Matsushita Memorial Hospital; hematology

location_facility: Chaim Sheba Medical Center; Hematology BMT & CBB

location_facility: St. Frankziskus Krankenhaus, Med. Klinik I; Klinik für Hämatologie,Onkologie u. Gastroenterologie

location_facility: Uni Göttingen, Georg-August-Universität; Klinik für Hämatologie und Medizinische Onkologie

location_facility: Semmelweis University, First Dept of Medicine

location_facility: Austin and Repatriation Medical Centre; Cancer Services

location_facility: Ospedale V. Cervello; U.O. Ematologia E Trapianti

location_facility: Ospedale Maggiore Di Milano; U.O. Ematologia I - Padiglione Marcora

location_facility: Vseobecna Fakultni Nemocnice v Praze, I. Interni Klinika - Klinika Hematoonkologie VFN a 1. LF UK

location_facility: Queen Elizabeth Hospital; Centre for Clinical Haematology

location_facility: Kath. Krankenhaus Hagen gem. GmbH, St.-Josefs-Hospital; Klinik für Hämatologie und Onkologie

location_facility: The Jikei University Daisan Hospital; Department of Clinical Oncology and Hematology

location_facility: National Taiwan Universtiy Hospital; Division of Hematology

location_facility: Gemeinschaftspraxis für Hämatologie und Onkologie

location_facility: Hyogo Cancer Center; Department of hematology

location_facility: Cancer Hospital Chinese Academy of Medical Sciences.

location_facility: University of Szeged, II Dept of Internal Medicine

location_facility: Corporacio Sanitaria Parc Tauli; Servicio de Hematologia

location_facility: Republican Clinical Hospital n.a. Baranov; Haematology

location_facility: Asst Grande Ospedale Metropolitano Niguarda; Dipartimento Di Ematologia Ed Oncologia

location_facility: Kumamoto University Hospital; Hematology Rheumatology and Clinical Immunology

location_facility: Union Hospital of Tongji Medical College, Dept. of Cancer Center; Cancer Center

location_facility: Chiba Cancer Center;Hematology and Oncology

location_facility: Fundacion Hospital de Alcorcon; Servicio de Hematologia

location_facility: Royal Bournemouth General Hospital; Haematology

location_facility: Krankenhaus Barmherziger Brüder; Klinik für Internistische Onkologie / Hämatologie

location_facility: Harbin Medical University Cancer Hospital

location_facility: St.-Antonius-Hospital gGmbH; Klinik für Hämatologie und Onkologie

location_facility: Nagoya City University Hospital; Hematology and Oncology

location_facility: Castle Hill Hospital; The Queens Centre for Oncology and Haematology

location_facility: Hospital Universitario la Paz; Servicio de Hematologia

location_facility: Hospital Univ. 12 de Octubre; Servicio de Hematologia

location_facility: Hospital Universitari Germans Trias i Pujol; Servicio de Hematologia

location_facility: Istituto Clinico Humanitas;U.O. Oncologia Medica Ed Ematologia

location_facility: Gemeinschaftspraxis Dr. med. Holger Klaproth

location_facility: Fakultni nemocnice Brno; Interni hematologicka a onkologicka klinika

location_facility: Dr. Georges L. Dumont University Hospital Centre

location_facility: Universitätsklinikum Essen; Innere Klinik und Poliklinik für Tumorforschung

location_facility: Nottingham City Hospital; Dept of Haematology

location_facility: Helsinki University Central Hospital; Dept of Oncology

location_facility: Kobe City Medical Center General Hospital; Hematology

location_facility: Universtitätsklinikum Ulm; Klinik für Innere Medizin III

location_facility: Fn Hr. Kralove; IV. Interni Hematologicka Klinika

location_facility: Leicester Royal Infirmary; Dept of Haematology

location_facility: UKSH, Campus Kiel; Klinik für Innere Medizin II, Hämatologie und Internistische Onkologie

location_facility: Hopital Saint Eloi; Hematologie Oncologie Medicale

location_facility: Klinikum Mannheim III. Medizinische Klinik

location_facility: Chu Estaing; Hematologie Clinique Adultes

location_facility: Tohoku University Hospital; Hematology and Immunology

location_facility: Niigata Cancer Center Hospital; Internal Medicine

location_facility: Princess Alexandra Hospital Woolloongabba; Clinical Hematology and Medical Oncology

location_facility: Jichi Medical University Hospital; Hematology

location_facility: Fujian Medical University Union Hospital

location_facility: Onkologische Schwerpunktpraxis Dres. Bernd Gaede, Hans-Ulrich Ehlers, Ulrike Rodewig u.w.

location_facility: Klinik Johann Wolfgang von Goethe Uni; Medizinische Klinik II

location_facility: Azienda Ospedaliera Universitaria di Modena

location_facility: Concord Repatriation General Hospital; Haematology

location_facility: Universitätsklinikum Freiburg; Klinik für Innere Medizin I; Hämatologie/Onkologie

title: A Multicenter, Phase III, Open-Label, Randomized Study in Previously Untreated Patients With Advanced Indolent Non-Hodgkin's Lymphoma Evaluating the Benefit of GA101 (RO5072759) Plus Chemotherapy Compared With Rituximab Plus Chemotherapy Followed by GA101 or Rituximab Maintenance Therapy in Responders

summary: This open-label, randomized study will assess the efficacy and safety of obinutuzumab (RO5072759) in combination with chemotherapy compared to rituximab (MabThera/Rituxan) with chemotherapy followed by obinutuzumab or rituximab maintenance in participants with untreated advanced indolent non-Hodgkin's lymphoma. After the end of the induction period, participants achieving response (Complete response [CR] or partial response [PR]) will undergo a maintenance period continuing on the randomized antibody treatment alone every 2 months until disease progression for a total of 2 years. Anticipated time on study treatment is up to approximately 2.5 years. After maintenance or observation, participants will be followed for 5 years until progression. After progression, participants will be followed for new anti-lymphoma therapy and overall survival until the end of the study.


lead_sponsor: Merck Sharp & Dohme Corp.

location_country:
Peru
Guatemala
Romania
Australia
Russian Federation
Denmark
France
Japan
Argentina
Canada
Korea, Republic of
Colombia
Switzerland
Ireland
United States
United Kingdom
Italy
Mexico
Israel
Spain
Turkey

acronym: Olaparib Monotherapy in HRRm or HRD Positive Cancer

location_facility: Christie NHS Foundation Trust ( Site 1601)

location_facility: Istanbul Universitesi Cerrahpasa Tip Fakultesi ( Site 1505)

location_facility: Instituto Nacional de Cancerologia E.S.E ( Site 2809)

location_facility: Policlinico Le Scotte di Siena ( Site 0704)

location_facility: Sociedad de Oncología Y Hematología del Cesar S.A.S. ( Site 2808)

location_facility: Virginia Mason Medical Center ( Site 0052)

location_facility: Hospital Universitario Quiron Madrid ( Site 1352)

location_facility: Arkhangelsk Clinical Oncological Dispensary ( Site 1204)

location_facility: Ege Universitesi Tip Fakultesi ( Site 1502)

location_facility: Memorial Sloan-Kettering Cancer Center at West Harrison ( Site 0126)

location_facility: Ospedale Regionale di Bellinzona e Valli ( Site 1407)

location_facility: Centro de Investigaciones Clinicas de Latinoamerica S.A. - CELAN ( Site 3004)

location_facility: Instituto de Investigaciones Metabolicas ( Site 2700)

location_facility: Hacettepe Universitesi Tıp Fakultesi ( Site 1503)

location_facility: Hospital Nacional Guillermo Almenara Irigoyen ( Site 3107)

location_facility: National Cancer Center Hospital East ( Site 2600)

location_facility: Seoul National University Hospital ( Site 2401)

location_facility: MNCCI Port Macquarie Base Hospital ( Site 2201)

location_facility: Hadassah Ein Kerem Medical Center ( Site 0802)

location_facility: CHUQ-Univ Laval-Hotel Dieu de Quebec ( Site 0204)

location_facility: Ryazan Regional Clinical Oncology dispensary ( Site 1202)

location_facility: Scientific Research Oncology Institute n.a. N.N.Petrov ( Site 1208)

location_facility: MEDSI Clinical Hospital on Pyatnitsky Highway-Departmentof Antitumor Drug therapy ( Site 1216)

location_facility: Centro Estatal de Cancerologia de Chihuahua ( Site 2907)

location_facility: Instituto de Oncologia y Radioterapia Clinica Ricardo Palma ( Site 3101)

location_facility: Linear Clinical Research Ltd ( Site 2202)

location_facility: University of Massachusetts ( Site 0017)

location_facility: Centro Regional de Sub Especialidades Medicas SA ( Site 3003)

location_facility: Memorial Sloan Kettering Cancer Center ( Site 0026)

location_facility: Administradora Country SA - Clinica del Country ( Site 2802)

location_facility: Institut de Cancerologie Strasbourg Europe ( Site 0613)

location_facility: Eastern Regional Medical Center, Inc. ( Site 0077)

location_facility: Centre Georges Francois Leclerc ( Site 0608)

location_facility: Weinberg Cancer Institute at Franklin Square ( Site 0054)

location_facility: S.C. Pelican Impex S.R.L Spitalul Clinic Pelican Oradea ( Site 1102)

location_facility: Göztepe Prof. Dr. Süleyman Yalçın Şehir Hastanesi-oncology ( Site 1506)

location_facility: Tallaght University Hospital ( Site 1652)

location_facility: Istituto Clinico Humanitas Research Hospital ( Site 0703)

location_facility: Trakya Universitesi Tip Fakultesi ( Site 1500)

location_facility: Republican Clinical Oncology Dispensary of Tatarstan MoH ( Site 1207)

location_facility: Hopital Maisonneuve-Rosemont CIUSSS de l Est de L Ile de Montreal ( Site 0203)

location_facility: SBHI Leningrad Regional Clinical Hospital ( Site 1206)

location_facility: St Joseph Heritage Healthcare-Oncology ( Site 0056)

location_facility: Sanford Hematology Oncology-Sioux Falls SD ( Site 0012)

location_facility: Clinica Colsanitas S.A. Sede Clinica Universitaria Colombia ( Site 2807)

location_facility: Instituto Nacional de Enfermedades Neoplasicas ( Site 3106)

location_facility: Hospital Militar Central Coronel Luis Arias Schereiber ( Site 3105)

location_facility: Necmettin Erbakan Universitesi Meram Tip Fakultesi ( Site 1507)

location_facility: S.C. Centrul de Oncologie Sf. Nectarie SRL ( Site 1103)

location_facility: Aichi Cancer Center Hospital ( Site 2602)

location_facility: Cancer Partners of Nebraska ( Site 0051)

location_facility: Clinical Hospital Saint Luka ( Site 1205)

location_facility: Severance Hospital Yonsei University Health System ( Site 2400)

location_facility: MSROI named after P.A. Hertsen branch of FSBI NMRC Radiology ( Site 1213)

location_facility: Mater Misericordiae University Hospital ( Site 1654)

location_facility: Oaxaca Site Management Organization S.C. ( Site 2905)

location_facility: Unidad Biomedica Avanzada Monterrey S. A. ( Site 2902)

location_facility: Northern Centre for Cancer Care ( Site 1602)

location_facility: CRYPTEX Investigacion Clinica S.A. de C.V. ( Site 2900)

location_facility: Akdeniz Universitesi Tip Fakultesi ( Site 1504)

location_facility: Cedars Sinai Medical Center ( Site 0002)

location_facility: Hospital Central de la Fuerza Aerea del Peru ( Site 3104)

location_facility: Hospital Britanico de Buenos Aires ( Site 2704)

location_facility: Memorial Sloan Kettering Cancer Center- Monmouth ( Site 0116)

location_facility: Consultorio de Medicina Especializada del Sector Privado ( Site 2904)

location_facility: Hospital de Alta Complejidad de La Libertad Virgen de La Puerta ( Site 3102)

location_facility: Winship Cancer Institute of Emory University ( Site 0025)

location_facility: The Cancer Institute Hospital of JFCR ( Site 2605)

location_facility: Hospital Universitari Vall d Hebron ( Site 1350)

location_facility: Baskent University Adana Training Hospital ( Site 1508)

location_facility: Clinica Internacional Sede San Borja ( Site 3100)

location_facility: Rocky Mountain Regional Veterans Affairs Medical Center ( Site 0092)

location_facility: Herlev og Gentofte Hospital. ( Site 0401)

location_facility: Laura and Isaac Perlmutter Cancer Center at NYU Langone Health ( Site 0057)

location_facility: The University of Arizona Cancer Center - North Campus ( Site 0011)

location_facility: UCSF Helen Diller Family Comprehensive Cancer Center ( Site 0007)

location_facility: Chelyabinsk Regional Clinical Oncological Dispensary ( Site 1212)

location_facility: Odense Universitetshospital ( Site 0400)

location_facility: Centro de Estudios de Investigacion Metabolicos y Cardiovasculares ( Site 2901)

location_facility: SC Radiotherapy Center Cluj SRL ( Site 1105)

location_facility: Veterans Affairs Puget Sound Health Care System [Seattle, WA] ( Site 0093)

location_facility: C. Medico Imbanaco Cali S.A. ( Site 2810)

location_facility: VA New York Harbor Healthcare System Manhattan ( Site 0094)

location_facility: St. Vincent's University Hospital ( Site 1653)

location_facility: SBHI Samara Regional Clinical Oncology Dispensary ( Site 1211)

location_facility: Universitaetsspital Zuerich ( Site 1400)

location_facility: Hopitaux Universitaires de Geneve HUG. ( Site 1406)

location_facility: Fundacion Centro de Investigacion Clinica CIC ( Site 2812)

location_facility: Actualidad Basada en la Investigacion del Cancer ( Site 2903)

location_facility: Centro de Oncologia e Investigacion Buenos Aires COIBA ( Site 2703)

location_facility: Istituto Nazionale Tumori Fondazione Pascale ( Site 0700)

location_facility: National Cancer Center Hospital ( Site 2601)

location_facility: Sunnybrook Health Science Centre ( Site 0210)

location_facility: Seoul National University Bundang Hospital ( Site 2402)

location_facility: Southwestern Regional Medical Center, Inc. ( Site 0079)

type: Other Identifier

type: Registry Identifier

title: A Phase 2 Study of Olaparib Monotherapy in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer

summary: This study will evaluate the efficacy and safety of olaparib (MK-7339) monotherapy in participants with multiple types of advanced cancer (unresectable and/or metastatic) that: 1) have progressed or been intolerant to standard of care therapy; and 2) are positive for homologous recombination repair mutation (HRRm) or homologous recombination deficiency (HRD).


ReferenceType: result

ReferenceCitation: Hillmen P, Brown JR, Eichhorst BF, Lamanna N, O'Brien SM, Qiu L, Salmi T, Hilger J, Wu K, Cohen A, Huang J, Tam CS. ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. Future Oncol. 2020 Apr;16(10):517-523. doi: 10.2217/fon-2019-0844. Epub 2020 Mar 24.

name: Department of Haematology, Leeds Teaching Hospitals NHS Trust, Level 3 Bexley Wing, St James's University Hospital, Leeds LS9 7TF, UK

family: Hillmen

full_name: Peter Hillmen

given: Peter

name: Dana-Farber Cancer Institute, Boston, MA 02215, USA

family: Brown

full_name: Jennifer R Brown

given: Jennifer R

name: Department of Internal Medicine, University of Cologne, Cologne 50923, Germany

family: Eichhorst

full_name: Barbara F Eichhorst

given: Barbara F

name: Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY 10032, USA

family: Lamanna

full_name: Nicole Lamanna

given: Nicole

name: Chao Family Comprehensive Cancer Center, University of California, Orange, CA 92868, USA

family: O’Brien

full_name: Susan M O’Brien

given: Susan M

name: Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, PR China

family: Qiu

full_name: Lugui Qiu

given: Lugui

name: BeiGene USA, Inc., San Mateo, CA 94403, USA

family: Salmi

full_name: Tommi Salmi

given: Tommi

family: Hilger

full_name: James Hilger

given: James

family: Wu

full_name: Kenneth Wu

given: Kenneth

family: Cohen

full_name: Aileen Cohen

given: Aileen

family: Huang

full_name: Jane Huang

given: Jane

name: Peter MacCallum Cancer Centre, St Vincent’s Hospital, University of Melbourne, Melbourne, Victoria 3000, Australia and University of Melbourne, Parkville, Victoria 3052, Australia

family: Tam

full_name: Constantine S Tam

given: Constantine S

journal_name: Future Oncology

oa_host_type: publisher

evidence: open (via page says license)

license: cc-by-nc-nd

license_normalized: cc-by-nc-nd

publisher: Future Medicine Ltd

publisher_dissemination: Future Science Ltd

publisher_group: Future Science Ltd

publisher_normalized: Future Science Ltd

lead_sponsor: BeiGene

location_country:
Italy
Sweden
Netherlands
Spain
Germany
France
Czechia
Poland
Belgium
Australia
New Zealand
China
Turkey
United States
United Kingdom

acronym: ALPINE

location_facility: Hospital Universitario Germans Trias i Pujol

location_facility: Centre Hospitalier Departemental de Vendee

location_facility: Hospital Universitario Marques de Valdecilla

location_facility: The Christie NHS Foundation Trust - PPDS

location_facility: Tianjin Medical University Cancer Institute and Hospital

location_facility: The First affiliated hospital of Nanchang University

location_facility: Quanzhou First Hospital of Fujian Province

location_facility: Rocky Mountain Cancer Centers (Aurora) - USOR

location_facility: Comprehensive Cancer Centers of Nevada - USOR

location_facility: Beijing Friendship Hospital-Capital Medical University

location_facility: The first affiliated hospital of Wenzhou Medical University

location_facility: Azienda Ospedaliera Città della Salute e della Scienza di Torino

location_facility: Hospital Universitari de Girona Dr Josep Trueta

location_facility: Illinois Cancer Specialists (Niles) - USOR

location_facility: Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Lodzi

location_facility: Hospital Universitario Central de Asturias

location_facility: Hospital Universitario Puerta de Hierro - Majadahonda

location_facility: Greenville Health System Cancer Institute

location_facility: Texas Oncology - San Antonio Medical Center - USOR

location_facility: Samodzielny Publiczny Zaklad Opieki Zdrowotnej Zespol Szpitali Miejskich

location_facility: University of California Irvine Medical Center

location_facility: Oncology and Hematology Associates of Southwest Virginia, Inc

location_facility: New Jersey Hematology Oncology Associates LLC

location_facility: ASST Grande Ospedale Metropolitano Niguarda - Presidio Ospedaliero Ospedale Niguarda Ca' Granda

location_facility: Hattiesburg Hematology and Oncology Clinic

location_facility: Wojewodzki Szpital Specjalistyczny w Legnicy

location_facility: Gemeinschaftspraxis fur Hamatologie und Onkologie

location_facility: Onkoligische Gemeinschaftspraxis Dres. Dörfel/Göhler

location_facility: Fondazione Policlinico Universitario A Gemelli

location_facility: Copernicus PL Sp. z o.o. Wojewodzkie Centrum Onkologii

location_facility: Joe Arrington Cancer Research and Treatment Center

location_facility: VA Puget Sound Health Care System - NAVREF

location_facility: Nottingham University Hospitals NHS Trust

location_facility: The affiliated Hospital of Xuzhou Medical university

location_facility: Fujian Medical University Union Hospital

location_facility: Texas Oncology-Baylor Charles A. Sammons Cancer Center

location_facility: Shengjing Hospital of China Medical University

location_facility: Hospital Universitario Vall d'Hebrón - PPDS

location_facility: Ohio State University Comprehensive Cancer Center

title: A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

summary: This study is designed to compare the overall response rate of zanubrutinib versus ibrutinib in participants with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.


location_country:
Italy
United States
Brazil
Chile
Netherlands
Germany
France
Czechia
Japan
Slovakia
Belgium
Australia
Spain
Turkey
Canada
United Kingdom
Korea, Republic of

title: A Randomised, Double-blind, Placebo-controlled, Multicentre Phase III Study of Olaparib Plus Abiraterone Relative to Placebo Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (PROpel Study)

summary: The purpose of this study is to evaluate the efficacy and safety (including evaluating side effects) of combination of olaparib and abiraterone versus placebo and abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) who have received no prior cytotoxic chemotherapy or new hormonal agents (NHAs) at metastatic castration-resistant prostate cancer (mCRPC) stage.


title: A Multicenter, Randomized, Double-blind, Active-Controlled Study of the Efficacy and Safety of Flexibly-Dosed BMS-820836 in Patients With Treatment Resistant Major Depression

summary: The purpose of the study is to evaluate the efficacy of study drug (BMS-820836) as compared with continued duloxetine in the treatment of patients with treatment resistant depression (TRD).

lead_sponsor: Bristol-Myers Squibb

location_country:
South Africa
Sweden
Finland
France
United States
Canada

location_facility: Oregon Center For Clinical Investigations, Inc (Occi, Inc)

location_facility: California Neuroscience Research Medical Group, Inc.

location_facility: K & S Professional Research Services, Llc

location_facility: Comprehensive Clinical Development, Inc.

location_facility: Dean Foundation For Health Research & Education

location_facility: Collaborative Neuroscience Network, Inc.

location_facility: Independent Psychiatric Consultants, Sc, Dba, Ipc Research

location_facility: University Of South Carolina School Of Medicine

location_facility: Belmont Center For Comprehensive Treatment

location_facility: Atlanta Institute Of Medicine & Research

location_facility: California Neuropsychopharmacology Clinical Research Inst.

location_facility: Oregon Center For Clinical Investigations, Inc. (Occi, Inc)


title: A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of IV Infusion Treatment With Omecamtiv Mecarbil in Subjects With Left Ventricular Systolic Dysfunction Hospitalized for Acute Heart Failure

summary: The primary objective of the study is to evaluate the effect of 48 hours of intravenous (IV) omecamtiv mecarbil compared with placebo on dyspnea in subjects with left ventricular systolic dysfunction hospitalized for acute heart failure. This is a multicenter, randomized, double-blind, placebo-controlled study with 3 dose cohorts enrolled sequentially in order of ascending dose strength of omecamtiv mecarbil. In each cohort, subjects are randomized 1:1 to omecamtiv mecarbil or placebo.

ReferenceCitation: Teerlink JR, Felker GM, McMurray JJV, Ponikowski P, Metra M, Filippatos GS, Ezekowitz JA, Dickstein K, Cleland JGF, Kim JB, Lei L, Knusel B, Wolff AA, Malik FI, Wasserman SM; ATOMIC-AHF Investigators. Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure: The ATOMIC-AHF Study. J Am Coll Cardiol. 2016 Mar 29;67(12):1444-1455. doi: 10.1016/j.jacc.2016.01.031.

family: Teerlink

full_name: John R. Teerlink

given: John R.

family: Felker

full_name: G. Michael Felker

given: G. Michael

family: McMurray

full_name: John J.V. McMurray

given: John J.V.

family: Ponikowski

full_name: Piotr Ponikowski

given: Piotr

family: Metra

full_name: Marco Metra

given: Marco

family: Filippatos

full_name: Gerasimos S. Filippatos

given: Gerasimos S.

family: Ezekowitz

full_name: Justin A. Ezekowitz

given: Justin A.

family: Dickstein

full_name: Kenneth Dickstein

family: Cleland

full_name: John G.F. Cleland

given: John G.F.

family: Kim

full_name: Jae B. Kim

given: Jae B.

family: Lei

full_name: Lei Lei

given: Lei

family: Knusel

full_name: Beat Knusel

given: Beat

family: Wolff

full_name: Andrew A. Wolff

given: Andrew A.

family: Malik

full_name: Fady I. Malik

given: Fady I.

family: Wasserman

full_name: Scott M. Wasserman

given: Scott M.

journal_name: Journal of the American College of Cardiology

oa_colors: green hybrid

evidence: open (via crossref license)

evidence: oa repository (via OAI-PMH doi match)

repository_institution: The University of Glasgow - Enlighten: Publications

repository_institution: Imperial College London - Spiral

version: submittedVersion

lead_sponsor: Cytokinetics

location_country:
Italy
United States
Netherlands
Germany
Finland
France
Bulgaria
Czechia
Greece
Lithuania
Norway
Hungary
Belgium
Australia
Poland
Russian Federation
Slovakia
Canada
United Kingdom


title: A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study of Cemiplimab Versus the Combination of Cemiplimab With ISA101b in the Treatment of Subjects With HPV16-Positive Oropharyngeal Cancer (OPC)

summary: This will be a blinded, placebo-controlled, randomized, phase 2 study in which subjects will be randomly assigned 1:1 to cemiplimab plus placebo or cemiplimab plus ISA101b.

lead_sponsor: ISA Pharmaceuticals

location_country:
Italy
United States
Netherlands
France
Czechia
Hungary
Belgium
Spain
Germany
United Kingdom

location_facility: University of Pecs Department of Oncotherapy

location_facility: Hospital Universitario Virgen de la Victoria

location_facility: Hospital Universitario Marqués de Valdecilla Santander

location_facility: Hospital Clnic i Provincial de Barcelona

location_facility: IKrankenhaus Nordwest gGmbH, nstitut für Klinisch-Onkologische Forschung

location_facility: Moores Cancer Center at the UC San Diego Health

location_facility: University of Cincinnati Cancer Institute

location_facility: UOC Oncologia Medica Ospedale di Sondrio

location_facility: Azienda Ospedaliera San Paolo Polo Universitario

location_facility: Washington University School of Medicine

location_facility: Azienda Sanitaria Universitaria Integrata di Udine

location_facility: Szabolcs Szatmar Bereg Megyei Korhazak Es Egyetemi Oktatokorhaz

location_facility: Hopitaux Universitaires Pitié Salpêtrière Charles Foix

location_facility: Hospital Duran i Reynals - Institut Catala dOncologia ICO

location_facility: Robert H. Lurie Comprehensive Cancer Center


title: Initiative for Patient Outcomes in Dialysis - PD (IPOD-PD Study)

acronym: IPOD-PD

summary: The aim of the study is to asses the hydration status of incident peritoneal dialysis (PD) patients and its evolution over a period of four years, independent of the PD treatment modality (APD or CAPD) and the PD solution type.

study_type: Observational

time_perspective: Prospective

ReferenceCitation: Ronco C, Verger C, Crepaldi C, Pham J, De Los Ríos T, Gauly A, Wabel P, Van Biesen W; IPOD-PD Study Group. Baseline hydration status in incident peritoneal dialysis patients: the initiative of patient outcomes in dialysis (IPOD-PD study)†. Nephrol Dial Transplant. 2015 May;30(5):849-58. doi: 10.1093/ndt/gfv013. Epub 2015 Mar 11.

family: Ronco

full_name: C. Ronco

given: C.

family: Verger

full_name: C. Verger

family: Crepaldi

full_name: C. Crepaldi

family: Pham

full_name: J. Pham

given: J.

family: De los Rios

full_name: T. De los Rios

given: T.

family: Gauly

full_name: A. Gauly

given: A.

family: Wabel

full_name: P. Wabel

given: P.

family: Van Biesen

full_name: W. Van Biesen

given: W.

journal_name: Nephrology Dialysis Transplantation

repository_institution: PubMed Central - Europe PMC

evidence: oa repository (semantic scholar lookup)

lead_sponsor: Fresenius Medical Care Deutschland GmbH

location_country:
Finland
Greece
Cuba
Belgium
Denmark
Czech Republic
India
Croatia
France
Lithuania
Norway
Korea, Republic of
Turkey
Sweden
Switzerland
Netherlands
Portugal
Germany
United Kingdom
Italy
Austria
Bosnia and Herzegovina
Brazil
Venezuela
Israel
Spain
Estonia
Latvia

location_facility: AUB Quimper / Centre Hospitalier Laennec

location_facility: General University Hospital of Alexandroupolis

location_facility: General Hospital of Athens G. Gennimatas

location_facility: General University Hospital of Thessaloniki "AHEPA"

location_facility: Nephrologisches Zentrum Velbert Innere Medizin und Nephrologie


title: Randomized, Multicenter, Double-Blind, Phase 3 Trial Comparing the Efficacy of Ipilimumab in Addition to Paclitaxel and Carboplatin Versus Placebo in Addition to Paclitaxel and Carboplatin in Subjects With Stage IV/Recurrent Non Small Cell Lung Cancer (NSCLC)

summary: The purpose of the study is to determine whether Ipilimumab plus Paclitaxel and Carboplatin will extend the lives of patients with squamous only non small cell lung cancer more than placebo plus Paclitaxel and Carboplatin.

location_country:
Peru
Romania
Australia
Belgium
Russian Federation
Denmark
Taiwan
France
Japan
Poland
Thailand
Argentina
Canada
Korea, Republic of
Colombia
South Africa
Chile
Sweden
Hong Kong
Netherlands
Switzerland
Singapore
Hungary
Ireland
China
Portugal
Germany
United States
United Kingdom
Italy
Austria
Brazil
Mexico
Czechia
Israel
Spain

location_facility: Presence Medical Group Hematology Oncology

location_facility: University Of Illinois At Chicago Medical Center

location_facility: Lynn Cancer Institute Center For Hematology-Oncology

location_facility: Wisconsin Institutes for Medical Research

location_facility: Oklahoma Oncology And Hematology, Pc Dba

location_facility: Southern Illinois University School Of Medicine

location_facility: Texas Oncology, PA - South Austin Cancer Center

location_facility: Washington University School Of Medicine


title: Studying Interventions for Managing Patients With Chronic Myeloid Leukemia (CML) in Chronic Phase: The 5-Year Prospective Cohort Study (SIMPLICITY)

acronym: SIMPLICITY

summary: The purpose of this study is to better understand the use of tyrosine kinase inhibitors (TKI) in patients newly diagnosed with CML and their quality of life in a real-world setting.

status: Unknown status

time_perspective: Other

ReferenceCitation: Hehlmann R, Cortes JE, Zyczynski T, Gambacorti-Passerini C, Goldberg SL, Mauro MJ, Michallet M, Simonsson B, Williams LA, Gajavelli S, DeGutis I, Sen GP, Paquette RL. Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic-phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY. Am J Hematol. 2019 Jan;94(1):46-54. doi: 10.1002/ajh.25306. Epub 2018 Oct 31.

name: Universität Heidelberg and ELN-Foundation; Weinheim Germany

family: Hehlmann

full_name: Rüdiger Hehlmann

given: Rüdiger

name: The University of Texas; MD Anderson Cancer Center; Houston Texas

family: Cortes

full_name: Jorge E. Cortes

given: Jorge E.

name: Bristol-Myers Squibb; Princeton New Jersey

family: Zyczynski

full_name: Teresa Zyczynski

given: Teresa

name: University of Milano Bicocca; San Gerardo Hospital; Monza Italy

family: Gambacorti-Passerini

full_name: Carlo Gambacorti-Passerini

given: Carlo

name: John Theurer Cancer Center; Hackensack University Medical Center; Hackensack New Jersey

family: Goldberg

full_name: Stuart L. Goldberg

given: Stuart L.

name: Memorial Sloan-Kettering Cancer Center; New York New York

family: Mauro

full_name: Michael J. Mauro

given: Michael J.

name: Centre Hospitalier Lyon-Sud; Pierre-Bénite France

family: Michallet

full_name: Mauricette Michallet

given: Mauricette

family: Simonsson

full_name: Bengt Simonsson

given: Bengt

name: The University of Texas MD Anderson Cancer Center; Houston Texas

family: Williams

full_name: Loretta A. Williams

given: Loretta A.

family: Gajavelli

full_name: Srikanth Gajavelli

given: Srikanth

family: DeGutis

full_name: Irene DeGutis

given: Irene

name: ICON Clinical Research LLC; South San Francisco California

family: Sen

full_name: Ginny P. Sen

given: Ginny P.

name: UCLA Medical Centre; Los Angeles California

family: Paquette

full_name: Ron L. Paquette

given: Ron L.

journal_name: American Journal of Hematology

repository_institution: KTH Royal Institute of Technology - KTH Publication Database DiVA

location_country:
Italy
United States
Netherlands
France
Puerto Rico
Russian Federation
Spain
Germany

location_facility: Cancer & Hematology Centers of Western Michigan

location_facility: Texas Oncology-Methodist Charlton Cancer Center

location_facility: Yakima Valley Memorial Hospital/North Star Lodge

location_facility: Indiana Blood and Marrow Transplantation

location_facility: Tahoe Forest Health System Cancer Center

location_facility: Veterans Research Foundation of Pittsburgh

location_facility: University of Louisville Hospital - Brown Cancer Center

location_facility: Texas Oncology-Dallas Presbyterian Hospital

location_facility: Providence Cancer Center at Sacred Heart Medical Center

location_facility: Signal Point Clinical Research Center, LLC

location_facility: Texas Oncology-Odessa West Texas Cancer Center

location_facility: Hematology-Oncology Associates of Northern NJ, PA

location_facility: Medical Oncology Associates of Wyoming Valley, PC

location_facility: Swedish Cancer Institute-Eastside Hematology/Oncology

location_facility: Little Rock Hematology Oncology Associates

location_facility: Investigative Clinical Research of Indiana

location_facility: St John's Clinic for Cancer and Hematology

location_facility: Washington Hospital Center, Washington Cancer Institute

location_facility: Hematology Oncology Associates of Fredricksburg

location_facility: City Hospital - West Virginia University Hospital East

location_facility: Hematology and Oncology Associates of RI

location_facility: Texas Oncology-Midland Allison Cancer Center

location_facility: Hematology And Medical Oncology Of Southern Palm Beach County

location_facility: Medical Oncology and Blood Disorders, LLP